Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression
Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression
Olivia M. Dean1,2,3, Alyna Turner1,4, Gin S. Malhi5,6, Chee Ng7, Sue M. Cotton8,9, Seetal Dodd1,3, Jerome Sarris3,10, Yuval Samuni1, Michelle Tanious5,6, Nathan Dowling7, Astrid Waterdrinker1, Deidre Smith7, Michael Berk1,2,3,8
Vol.37 Issue 1/2015: